VolitionRx Limited Announces Final Results from 8000 Patient Clinical Trial in Denmark to Evaluate the Performance of its Nu.Q(TM) Triage Test.

New data confirms prior test results that Volition's novel blood test can accurately detect colorectal cancer and reduce colonoscopies

NAMUR, Belgium, May 9, 2017 /PRNewswire/ -- At the Digestive Disease Week 2017 (DDW) in Chicago, VolitionRx Limited (NYSE MKT: VNRX) presented results that continue to show that the Nu.QTM Colorectal Cancer Screening Triage Test reduces the total number of colonoscopy referrals while maintaining high sensitivity for cancer detection.

"We have successfully completed this key clinical milestone in the launch of our Nu.QTM Triage product. This study, with the total cohort totalling just under 8000 subjects demonstrates that the Nu.QTM Triage test was able to prevent 24.5% of colonoscopies and detect almost 95% of colorectal cancers and 87.9% of high-risk adenomas. It further strengthens the case for the Nu.QTM Colorectal Cancer Screening Triage test to be incorporated into colorectal cancer screening programs," said Louise Day, Chief Marketing and Communications Officer at Volition.

Professor Hans Jorgen Nielsen from Hvidovre Hospital, University of Copenhagen, commented, "These results, from a very large data set, confirm that the Nu.QTM Triage test has the potential to accelerate the diagnosis of colorectal cancer, by reducing the number of unnecessary colonoscopies being performed thereby allowing more people to be screened quickly and effectively."

The presentation from the DDW can be found and downloaded at www.volitionrx.com

About Volition

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present.

As cancer screening programs become more and more widespread, our products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are currently centered in Belgium, with additional offices in London, New York, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

For more information about Volition, visit Volition's website (http://www.volitionrx.com) or connect with us via:

Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx

The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media / Investor Contacts

Louise Day, Volition


+44 (0)7557 774620

Scott Powell, Volition


+1 (646) 650 1351

Tirth Patel, Edison Advisors


+1 (646) 653 7035

Rachel Carroll, Edison Advisors


+44 (0)20 3077 5711

Sarah Roberts, Vane Percy & Roberts


+44 (0)1737 821 890

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of Volition's bodily-fluid-based diagnostic tests as well as Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic products Volition might develop; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics®, NuQ®, Nu.QTM and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/volitionrx-limited-announces-final-results-from-8000-patient-clinical-trial-in-denmark-to-evaluate-the-performance-of-its-nuqtm-triage-test-300454011.html

SOURCE VolitionRx Ltd